A journey through the FDA’s newly released complete response letters gave glimpses into the journeys to market for Eli ...

Biogen shares slipped on Monday after the company said it expects to take a $46 million charge in the second quarter related ...

Ionis plans phase 3 trial of its antisense therapy for Angelman syndrome, shortly after Biogen decided against exercising an option to license the drug.

The increasing incidence of genetic and rare diseases is a major factor driving revenue growth in the Antisense ...

Sarepta Therapeutics Inc. research and ratings by Barron's. View SRPT revenue estimates and earnings estimates, as well as in-depth analyst breakdowns.

Biogen is looking to the future of its spinal muscular atrophy (SMA) business, taking a candidate offering once-yearly dosing into phase 3.

However, they said the FDA’s move could still create some sentiment overhang for Biogen and other named firms, including Sarepta (NASDAQ: SRPT), Alkermes, Biohaven, Xenon, and Argenx (NASDAQ: ARGX).

Find the latest Ionis Pharmaceuticals, Inc. (IONS) stock quote, history, news and other vital information to help you with your stock trading and investing.

Notable analyst calls this week: Sarepta, Cisco and UBS among top picks SA NewsSat, Jun. 21 ...